MedTrace Logo

Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)

NCT02596256 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2018-04-17

No results posted yet for this study

Summary

Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.

Conditions

Interventions

DRUG

Apatinib

Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity

DRUG

Docetaxel

Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity

Sponsors & Collaborators

  • Chinese PLA General Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2019-02-28
Completion
2019-02-28

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02596256 on ClinicalTrials.gov